Essa Pharma Inc (TSXV: EPI) is one of this year’s Venture 50 companies — this pharmaceutical company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer.



The company has developed a new class of drugs called the “anitens.” These drugs interrupt androgen-driven biology in a novel manner and are active even in the setting of resistance to current anti-androgen therapies. The company also created the drug, EPI-7386 to help treat men with prostate cancer.

The 2020 Venture 50 is a ranking of top performers on TSX Venture Exchange over the last year. The ranking comprises 10 companies from each of the five industry sectors, selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume.

For the full 2020 Venture 50 ranking, methodology and profile videos of companies included in the ranking, visit: